Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus
prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)
Open-label, randomized phase II trial in patients with symptomatic bone-only metastatic
castration-resistant prostate cancer. Eligible patients are randomly assigned into two arms:
- Arm A: radium-223 initially followed by docetaxel plus prednisone at the time of
progression (the second step is optional according to clinical evolution of disease)
- Arm B: docetaxel plus prednisone initially followed by radium-223 at the time of
progression (the second step is optional according to clinical evolution of disease).
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori